Abstract
Extracellular signal-regulated kinase (ERK)1/2 signalling mediates communication between growth factor receptors and the cell nucleus and has been linked to several key events in the transformation process such as proliferation and invasion. We therefore sought to delineate the degree of phosphorylated ERK1/2 in breast cancer and potential links to upstream receptors such as VEGFR2, ErbB2, downstream targets, such as Ets-2, as well as clinico-pathological parameters, clinical outcome and response to tamoxifen. ERK1/2 phosphorylation was assessed by immunohistochemistry using a phospho-specific ERK1/2 antibody in three breast cancer cohorts including a total of 886 tumours arranged in tissue arrays. Cohort I consisted of 114 patients, cohort II of 248 postmenopausal patients randomized to either 2 years of tamoxifen or no adjuvant treatment and cohort III of 524 patients. Surprisingly, ERK1/2 phosphorylation correlated inversely with tumour size. Phosphorylated ERK1/2 was further associated with the presence of VEGFR2 (cohorts II and III) and the degree of phosphorylated Ets-2, indicating in vivo, a signalling cascade from VEGFR2 via ERK1/2 to Ets-2 phosphorylation. Interestingly, ERK1/2 phosphorylation correlated with better survival in untreated patients independently of lymph-node status and tumour size indicating that ERK1/2 signalling might be associated with a less aggressive phenotype. Finally, patients with oestrogen receptor positive and ERK1/2 phosphorylated tumours also had an impaired tamoxifen response.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH and Murphy LC . (2002). Clin. Cancer Res., 8, 1747–1753.
Bottazzi ME, Zhu X, Bohmer RM and Assoian RK . (1999). J. Cell Biol., 146, 1255–1264.
Catalano A, Caprari P, Rodilossi S, Betta P, Castellucci M, Casazza A, Tamagnone L and Procopio A . (2003). FASEB J., 18, 358–360.
Chen Q, Kinch M, Lin T, Burridge K and Juliano R . (1994). J. Biol. Chem., 269, 26602–26605.
Cobb MH and Goldsmith EJ . (1995). J. Biol. Chem., 270, 14843–14846.
Collaborative GEBCT . (1998). Lancet, 351, 1451–1467.
Cross MJ, Dixelius J, Matsumoto T and Claesson-Welsh L . (2003). Trends Biochem. Sci., 28, 488–494.
De Placido S, Carlomagno C, De Laurentiis M and Bianco AR . (1998). Breast Cancer Res. Treat., 52, 55–64.
Fowles LF, Martin ML, Nelsen L, Stacey KJ, Redd D, Clark YM, Nagamine Y, McMahon M, Hume DA and Ostrowski MC . (1998). Mol. Cell. Biol., 18, 5148–5156.
Gee JM, Robertson JF, Ellis IO and Nicholson RI . (2001). Int. J. Cancer, 95, 247–254.
Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J and Lannigan DA . (1998). Mol. Cell. Biol., 18, 1978–1984.
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D and Chambon P . (1995). Science, 270, 1491–1494.
Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW and Thomas KA . (1999). J. Biol. Chem., 274, 6453–6460.
Kollermann J and Helpap B . (2001). Am. J. Clin. Pathol., 116, 115–121.
Lodén M, Nielsen N, Roos G, Emdin S and Landberg G . (1999). Oncogene, 19, 2557–2566.
Lodén M, Perris F, Nielsen N, Emdin S and Landberg G . (2003). Anticancer Res., 23, 2053–2061.
Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F and Eppenberger U . (2000). Int. J. Cancer, 89, 384–388.
Nielsen N, Emdin S, Cajander J and Landberg G . (1997). Oncogene, 14, 295–304.
Ohtani N, Zebeede Z, Hout T, JA S, Sugimoto M, Ohashi Y, Sharrocks A, Peters G and Hara E . (2001). Nature, 409, 1067–1070.
Roovers K and Assoian R . (2000). BioEssays, 22, 818–826.
Roovers K, Davey G, Zhu X, Bottazzi ME and Assoian RK . (1999). Mol. Biol. Cell, 10, 3197–3204.
Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE and Landberg G . (2003). Breast Cancer Res. Treat., 82, 147–154.
Sahl B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D and Pelech S . (1999). Anticancer Res., 19, 731–740.
Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng M-H and Yue W . (2002). J. Steroid Biochem. Mol. Biol., 80, 239–256.
Schaeffer HJ and Weber MJ . (1999). Mol. Cell. Biol., 19, 2435–2444.
Sewing A, Wiseman B, Lloyd A and Land H . (1997). Mol. Cell. Biol., 17, 5588–5597.
Sivaraman VS, Wang H-y, Nuovo GJ and Malbon CC . (1997). J. Clin. Invest., 99, 1478–1483.
Smith JL, Schaffner AE, Hofmeister JK, Hartman M, Wei G, Forsthoefel D, Hume DA and Ostrowski MC . (2000). Mol. Cell. Biol., 20, 8026–8034.
Stendahl M, Kronblad AA, Ryden L, Emdin S, Bengtsson NO and Landberg G . (2004). Br. J. Cancer, 90, 1942–1948.
Takahashi T and Shibuya M . (1997). Oncogene, 14, 2079–2089.
Takahashi T, Ueno H and Shibuya M . (1999). Oncogene, 18, 2221–2230.
Takahashi T, Yamaguchi S, Chida K and Shibuya M . (2001). EMBO J., 20, 2768–2778.
Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD and Ellis LM . (1996). Clin. Cancer Res., 2, 1679–1684.
von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B and Rosewicz S . (2000). Gastroenterology, 119, 1358–1372.
Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S and Fujinaga K . (1998). Int. J. Cancer, 77, 128–137.
Weber J, Raben D, Phillips P and Baldassare J . (1997). Biochem. J., 15, 61–68.
Wetzker R and Böhmer F . (2003). Nat. Rev. Mol. Cell. Biol., 4, 651–657.
Yang B, Hauser C, Henkel G, Colman M, Van Beveren C, Stacey K, Hume D, Maki R and Ostrowski M . (1996). Mol. Cell. Biol., 16, 538–547.
Acknowledgements
The authors are grateful for excellent technical assistance from Ms Elise Nilsson. This study was supported by grants from the Swedish Cancer Society, Lund University Research Funds, Malmö University Hospital Research and Cancer Funds, Gunnar, Arvid and Elisabeth Nilssons Cancer Foundation, Per-Erich and Ulla Schybergs Foundation and the Swegene/Wallenberg Consortium North (WCN).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Svensson, S., Jirström, K., Rydén, L. et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24, 4370–4379 (2005). https://doi.org/10.1038/sj.onc.1208626
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208626
Keywords
This article is cited by
-
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
Nature Cancer (2021)
-
Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals
Breast Cancer Research and Treatment (2017)
-
Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells
Breast Cancer Research and Treatment (2017)
-
The Aurora kinase inhibitors in cancer research and therapy
Journal of Cancer Research and Clinical Oncology (2016)
-
Heterogeneity in ERK activity as visualized by in vivo FRET imaging of mammary tumor cells developed in MMTV-Neu mice
Oncogene (2015)